5858 Horton Street
Suite 455
Emeryville, CA 94608
United States
510 505 2680
https://www.4dmoleculartherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 147
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. John F. Milligan Ph.D. | Executive Chairman | 150k | N/A | 1961 |
Dr. David H. Kirn M.D. | Co-Founder, CEO & Director | 1.01M | N/A | 1963 |
Dr. Fariborz Kamal Ph.D. | President & COO | 786.2k | N/A | 1963 |
Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Officer | 201.29k | N/A | 1963 |
Dr. Robert Y. Kim M.B.A., M.D. | Chief Medical Officer | 704.84k | N/A | 1961 |
Ms. Theresa Janke | Co-Founder & Chief of Staff | 652.32k | N/A | 1975 |
Mr. Uneek Mehra | Chief Financial & Business Officer | N/A | N/A | 1972 |
Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | N/A | N/A | 1973 |
Dr. An Song Ph.D. | Chief Development Officer | N/A | N/A | N/A |
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. | Senior VP & Therapeutic Area Head of Pulmonology | N/A | N/A | 1961 |
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
4D Molecular Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.